Targeting BCL2 pathways in CLL: a story of resistance and ingenuity

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Chronic lymphocytic leukemia (CLL) is a prevalent hematologic malignancy.
• Recent therapeutic advances include targeted agents like BCL2 inhibitors, BTK inhibitors, and CD20 antibodies.
• Treatment resistance remains a significant clinical challenge in managing CLL.

Purpose of the Study:

• To review the diverse mechanisms of resistance to BCL2 inhibitors in CLL.
• To explore emerging therapeutic strategies for overcoming treatment resistance in CLL.

Main Methods:

• Literature review of studies on CLL treatment resistance.
• Analysis of molecular and genetic mechanisms underlying resistance.
• Evaluation of novel therapeutic agents and approaches.

Main Results:

• Resistance mechanisms include BCL2 mutations, pathway alterations, epigenetic changes, and Richter transformation.
• Novel agents like bispecific antibodies, BTK degraders, and CAR T-cell therapy show promise.
• Understanding resistance pathways is crucial for developing effective treatment combinations.

Conclusions:

• Addressing resistance to targeted therapies is essential for improving CLL patient outcomes.
• Next-generation therapies offer new hope for patients with refractory or relapsed CLL.
• Further research into resistance mechanisms and combination strategies is warranted.